Protagonist Therapeutics (PTGX) Assets Average (2016 - 2026)

Protagonist Therapeutics has reported Assets Average for 11 years, with the latest figure at $682.8 million in Q1 2026.

• Quarterly Assets Average fell 8.15% year-over-year to $682.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $682.8 million (down 8.15% YoY) and the FY2025 annual result came in at $706.5 million, up 28.13% from the prior year.
• Assets Average steadied at $682.8 million in Q1 2026 per PTGX's latest filing, from $684.9 million in the prior quarter.
• Over five years, Assets Average peaked at $743.4 million in Q1 2025 and troughed at $243.9 million in Q1 2023.
• A 5-year average of $493.1 million and a median of $493.6 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2023 and 2024: Assets Average fell 29.91% in 2023, then surged 122.0% in 2024.
• Over 5 years, Assets Average stood at $265.1 million in 2022, then rose by 29.78% to $344.0 million in 2023, then surged by 96.02% to $674.3 million in 2024, then gained by 1.58% to $684.9 million in 2025, then fell by 0.31% to $682.8 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $682.8 million, $684.9 million, and $709.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.